Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
Recruiting
Observational Study
Type 2 Diabetes Mellitus (T2DM)
Metabolic Dysfunction-Associated Steatotic Liver Disease
Biological Age
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 20 – 90
- Sex
- Any
- Study type
- Observational
- Participants needed
- 2,720 (estimated)
- Sponsor
- Ningbo No. 1 Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the ris…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Abdominal ultrasound data available in annual health check-up records
2. At least one of the following five metabolic indicators recorded annually:
(1) Body mass index (BMI) or waist circumference (2) Blood pressure (3) Serum triglycerides (4) High-density lipoprotein choles…
Contacts